The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Published:2018-04 Issue:2 Volume:18 Page:95-113
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Blackwell Kimberly,Gligorov Joseph^ORCID,Jacobs Ira,Twelves Chris

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference87 articles.

1. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group;Seshadri;J Clin Oncol,1993

2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update;Wolff;J Clin Oncol,2013

3. Herceptin (trastuzumab) [US prescribing information]. South San Francisco, CA: Genentech, Inc; 2017.

4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger;Cardoso;Ann Oncol,2014

5. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study;Clinical Drug Investigation;2024-06-27

2. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data;BMC Public Health;2024-05-14

3. The Lancet Breast Cancer Commission;The Lancet;2024-05

4. Higher disease burden and lower utilization in mongolian with breast cancer: a 9-year retrospective cohort study of 18.19 million adults in China;International Journal of Surgery;2024-04-11

5. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union;Future Oncology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3